Alx Oncology (ALXO) Trading Snapshot
Alx Oncology (ALXO) experienced a modest decline of –1.68 % during the 24‑hour trading window that closed at 08:37 AM Central Europe on Monday, 26 November 2026. The stock is currently valued at USD 1.17 on major exchanges, with a total float of 138.3 million shares.
- Market Capitalisation: USD 161.8 million
- 24‑Hour Volume: USD 651 thousand
- Year‑to‑Date Performance: Down 13.65 % since the previous month‑end
- 200‑Day Simple Moving Average: USD 1.83
- 52‑Week High/Low: USD 2.66 (19 Feb 2026) / USD 0.86 (15 Oct 2026)
These figures illustrate a company that remains within a narrow trading band but has suffered a notable seasonal pullback. The recent dip aligns with broader sector volatility and the company’s ongoing clinical development milestones.
Peer Comparison – 24‑Hour Movements
| Ticker | Recent % Move | Current Price (USD) | Market Cap (USD mn) | P/E Ratio (if applicable) |
|---|---|---|---|---|
| Bassett Furniture Inds (BSET) | +0.45 % | 22.13 | 191.4 | 28.2 |
| Motorcar Parts Of America (MPAA) | +0.39 % | 10.18 | 192.7 | — |
| Silver Bow Mining (SBMT) | +1.87 % | 6.52 | 192.5 | — |
| Dhi (DHX) | –2.52 % | 4.64 | 192.4 | 162.11 |
| Niagen Bioscience (NAGE) | –3.57 % | 2.43 | 193.5 | 12.73 |
While Alx Oncology’s decline is modest relative to its peers, it is noteworthy that the company’s price trajectory sits near the lower end of its 52‑week range. In contrast, Silver Bow Mining and Bassett Furniture Inds have posted modest gains, suggesting sector‑specific momentum disparities.
Company Overview
Alx Oncology Holdings Inc. is a clinical‑stage immuno‑oncology enterprise headquartered in Burlingame, California. The firm focuses on developing therapies that harness both innate and adaptive immune responses to combat cancer. With a portfolio of investigational candidates, Alx Oncology targets a range of solid tumours, positioning itself as a potential disruptor in the oncology therapeutics landscape.
Key operational highlights:
- Research & Development: Multiple phase I/II programs in early‑stage evaluation.
- Regulatory Milestones: Recent filing of a New Drug Application (NDA) for its lead candidate in select indications.
- Strategic Partnerships: Collaborations with leading academic institutions to accelerate translational research.
For more detailed information, visit the company’s official website at www.alxoncology.com or review filings available on the Nasdaq exchange.
Forward‑Looking Perspective
Despite the recent dip, Alx Oncology’s trajectory remains anchored by a robust pipeline and a strategic emphasis on precision immuno‑therapy. The firm’s market cap, while modest, reflects investor confidence in its long‑term potential. Analysts anticipate that the upcoming quarterly earnings report and forthcoming clinical data will be critical in determining the stock’s next directional shift.
Investors should monitor:
- Clinical Trial Outcomes: Success of ongoing phase I/II studies.
- Regulatory Decisions: Potential approvals or setbacks from the FDA.
- Capital Structure Adjustments: Any new financing rounds or asset acquisitions that could alter share dilution dynamics.
In sum, Alx Oncology presents a compelling, albeit volatile, investment thesis for stakeholders who are comfortable with the inherent risks of early‑stage biopharmaceutical ventures.
